A Phase 2 multi-center, investigator masked, 28-day, parallel group, dose-finding study of NCX-470 in adult subjects with elevated intraocular pressure (IOP) due to open-angle glaucoma or ocular hypertension

Trial Profile

A Phase 2 multi-center, investigator masked, 28-day, parallel group, dose-finding study of NCX-470 in adult subjects with elevated intraocular pressure (IOP) due to open-angle glaucoma or ocular hypertension

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs NCX 470 (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus First in man; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2018 According to a Nicox media release, the company plans to submit IND to the US FDA in Q1 2019
    • 19 Dec 2017 According to a Nicox media release, the company plans to submit an Investigational New Drug (IND) application for NCX 470 to the US FDA in the summer of 2018.
    • 24 Oct 2017 According to a Nicox media release, IND filling is anticipated in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top